The existence of a subpopulation of undifferentiated cells with stem-like properties has been suggested in neuroblastoma tumors, but a definitive biomarker for their successful isolation is missing. Here we describe an in vitro culture system for the enrichment in undifferentiated stem-like tumor cells for subsequent functional assays. We make...
-
March 28, 2022 (v1)PublicationUploaded on: December 4, 2022
-
May 18, 2020 (v1)Publication
Pediatric tumors arise upon oncogenic transformation of stem/progenitor cells during embryonic development. Given this scenario, the existence of non-tumorigenic stem cells included within the aberrant tumoral niche, with a potential role in tumor biology, is an intriguing and unstudied possibility. Here, we describe the presence and function...
Uploaded on: December 5, 2022 -
May 16, 2022 (v1)Publication
No description
Uploaded on: March 25, 2023 -
April 22, 2020 (v1)Publication
No description
Uploaded on: March 25, 2023 -
November 11, 2019 (v1)Publication
BACKGROUND: Neuroblastoma is a paediatric tumour originated from sympathoadrenal precursors and characterized by its heterogeneity and poor outcome in advanced stages. Intra-tumoral cellular heterogeneity has emerged as an important feature in neuroblastoma, with a potential major impact on tumour aggressiveness and response to therapy. CD44 is...
Uploaded on: March 26, 2023 -
October 28, 2024 (v1)Publication
Pediatric tumors arise upon oncogenic transformation of stem/progenitor cells during embryonic development. Given this scenario, the existence of non-tumorigenic stem cells included within the aberrant tumoral niche, with a potential role in tumor biology, is an intriguing and unstudied possibility. Here, we describe the presence and function...
Uploaded on: October 29, 2024 -
October 19, 2021 (v1)PublicationIdentification of vrk1 as a new neuroblastoma tumor progression marker regulating cell proliferation
Neuroblastoma (NB) is one of the most common pediatric cancers and presents a poor survival rate in affected children. Current pretreatment risk assessment relies on a few known molecular parameters, like the amplification of the oncogene MYCN. However, a better molecular knowledge about the aggressive progression of the disease is needed to...
Uploaded on: March 25, 2023